Bayer #14373 - 4-week, open-label, multiple-dose study of the safety and the pharmacokinetic and pharmacodynamic properties of the oral direct factor Xa inhibitor rivaroxaban

Project: Research project

Project Details

StatusFinished
Effective start/end date3/15/1310/31/18

Funding

  • Bayer HealthCare Pharmaceuticals, Inc. (14373)